Abstract | PURPOSE: MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained for the HIPAA-compliant study. In 256 patients with LAM (mean age, 44 years) and 67 patients with TSC/ LAM (mean age, 40 years), CT scans of the chest, abdomen, and pelvis were reviewed by a single radiologist. The fraction of lung involvement with cysts was estimated from high-spatial-resolution CT scans. Other findings assessed included noncalcified pulmonary nodules, pleural effusion, thoracic duct dilatation, hepatic and renal angiomyolipomas (AMLs), lymphangioleiomyoma (LALM), ascites, nephrectomy, and renal embolization. Confidence intervals and hypothesis tests of differences in frequencies, comparison of age quartiles, RIDIT analysis, analysis of variance, and correlation coefficients were used in the statistical analysis. RESULTS: Patients with LAM had more extensive lung involvement (RIDIT score, 0.36) and higher frequency of LALM (29% vs 9%, P<.001), thoracic duct dilatation (4% vs 0, P=.3), pleural effusion (12% vs 6%, P=.2), or ascites (10% vs 6%, P=.3). Patients with TSC/ LAM had higher frequency of noncalcified pulmonary nodules (12% vs 1%, P<.01), hepatic (33% vs 2%, P<.001) and renal (93% vs 32%, P<.001) AMLs, nephrectomy (25% vs 7%, P<.001), or renal artery embolization (9% vs 2%, P<.05). CONCLUSION:
|
Authors | Nilo A Avila, Andrew J Dwyer, Antoinette Rabel, Joel Moss |
Journal | Radiology
(Radiology)
Vol. 242
Issue 1
Pg. 277-85
(Jan 2007)
ISSN: 0033-8419 [Print] United States |
PMID | 17105849
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Intramural)
|
Copyright | Copyright (c) RSNA, 2006. |
Topics |
- Adult
- Aged
- Comorbidity
- Diagnosis, Differential
- Female
- Humans
- Lymphangioleiomyomatosis
(diagnostic imaging, epidemiology)
- Male
- Middle Aged
- Prevalence
- Reproducibility of Results
- Sensitivity and Specificity
- Tomography, X-Ray Computed
(statistics & numerical data)
- Tuberous Sclerosis
(diagnostic imaging, epidemiology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|